Nigel Burns

Bio

Currently acting as an advisor to companies, venture capitalists and governments building on his 20 years of experience in the biotechnology field. Spent 9 years as part of the Senior Management Team at Cambridge Antibody Technology initially as Senior Vice President of Preclinical Development. Built and managed CaT’s capabilities to link their platform technology to clinical trials and established and chaired the company’s pipeline management committee. In 2004 became Senior Vice President responsible for CaT’s strategic alliances. In 2006 CaT was bought for $1.3 billion by Astra Zeneca following a very successful and productive 18 month collaboration between the two companies. Previously worked with British Biotech (now part of Vernalis) where he headed the Process Technology Division and played a significant role in developing its biotechnology-based products. Prior to this held scholarships at the Central Drug Research Institute, Lucknow, India, and at the California Institute of Technology. PhD in Biophysics from King’s College London.